MedRhythms, a Portland-based company that combines sensors, neuroscience and music to help people recover from neurologic injury or disease, announced Friday it raised $5 million in an oversubscribed Series A Financing round. The company stated in a news release that it intended to raise $4 million but due to substantial interest it raised the offering to $5.3 million. By the time of Friday’s announcement, it had raised $5 million. This investment will allow MedRhythms to develop and launch a patent-pending digital therapeutics platform that focuses on building evidence-based, FDA-approved, prescription products for people with neurologic injuries and diseases to improve and measure walking. While the first product on the platform focuses on the post-stroke population, the pipeline includes products for Parkinson’s disease, multiple sclerosis, aging-In-place and traumatic brain injury. Read more here.